Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Cloudbreak Pharma, Inc. ( (HK:2592) ).
Cloudbreak Pharma Inc. announced its unaudited consolidated interim results for the first half of 2025, showing a significant turnaround with a profit of $5.19 million compared to a loss of $52.11 million in the previous year. This improvement is largely attributed to a substantial change in the fair value of financial liabilities, despite increased general and administrative expenses and a continued focus on research and development.
More about Cloudbreak Pharma, Inc.
Cloudbreak Pharma Inc. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company focuses on research and development, as evidenced by its significant investment in R&D expenses.
Average Trading Volume: 2,145,927
For an in-depth examination of 2592 stock, go to TipRanks’ Overview page.